Which has preferable earnings & valuation, BMEA or RCKT?

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.29 N/A Rocket Pharmaceuticals N/A N/A -$223.12M -$0.17 N/A

Is BMEA or RCKT more profitable?

Rocket Pharmaceuticals' return on equity of -52.77% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -253.73% -97.91% Rocket Pharmaceuticals N/A -52.77% -44.92%

Does the media favor BMEA or RCKT?

In the previous week, Biomea Fusion and Biomea Fusion both had 4 articles in the media. Biomea Fusion's average media sentiment score of 0.72 beat Rocket Pharmaceuticals' score of 0.19 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rocket Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to FHTX or BMEA?

In the previous week, Biomea Fusion had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 1 mentions for Foghorn Therapeutics. Biomea Fusion's average media sentiment score of 0.72 beat Foghorn Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biomea Fusion 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, BMEA or DMAC?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biomea Fusion N/A N/A -$61.80M -$0.29 N/A DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A

Is BMEA or DMAC more profitable?

DiaMedica Therapeutics' return on equity of -77.76% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -253.73% -97.91% DiaMedica Therapeutics N/A -77.76% -69.43%

Which has stronger valuation & earnings, IPSC or BMEA?

Biomea Fusion is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Century Therapeutics N/A N/A -$9.58M -$0.93 N/A Biomea Fusion N/A N/A -$61.80M -$0.29 N/A

Is IPSC or BMEA more profitable?

Century Therapeutics' return on equity of -49.51% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Century Therapeutics N/A -49.51% -38.09% Biomea Fusion N/A -253.73% -97.91%

Does the media prefer IPSC or BMEA?

In the previous week, Biomea Fusion had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.57 beat Biomea Fusion's score of 0.72 indicating that Century Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Century Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biomea Fusion 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BMEA or SGMT more profitable?

Sagimet Biosciences' return on equity of -31.96% beat Biomea Fusion's return on equity. Company Net Margins Return on Equity Return on Assets Biomea Fusion N/A -253.73% -97.91% Sagimet Biosciences N/A -31.96% -30.57%

Does the media favor BMEA or SGMT?

In the previous week, Biomea Fusion and Biomea Fusion both had 4 articles in the media. Sagimet Biosciences' average media sentiment score of 0.97 beat Biomea Fusion's score of 0.72 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Biomea Fusion (BMEA) Competitors

$1.72 +0.13 (+7.86%)

As of 02:47 PM Eastern

Compare

BMEA vs. RCKT, FHTX, DMAC, IPSC, and SGMT

Should you buy Biomea Fusion stock or one of its competitors? Biomea Fusion's main competitors and comparable companies include Rocket Pharmaceuticals (RCKT), Foghorn Therapeutics (FHTX), DiaMedica Therapeutics (DMAC), Century Therapeutics (IPSC), and Sagimet Biosciences (SGMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biomea Fusion compare to Rocket Pharmaceuticals?

Biomea Fusion (NASDAQ:BMEA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Rocket Pharmaceuticals' return on equity of -52.77% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-253.73%	-97.91%
Rocket Pharmaceuticals	N/A	-52.77%	-44.92%

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$0.17	N/A

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Biomea Fusion and Biomea Fusion both had 4 articles in the media. Biomea Fusion's average media sentiment score of 0.72 beat Rocket Pharmaceuticals' score of 0.19 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biomea Fusion currently has a consensus target price of $8.20, suggesting a potential upside of 378.13%. Rocket Pharmaceuticals has a consensus target price of $8.57, suggesting a potential upside of 126.52%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Rocket Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30

Biomea Fusion has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Summary

Rocket Pharmaceuticals beats Biomea Fusion on 7 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Foghorn Therapeutics currently has a consensus price target of $11.43, indicating a potential upside of 63.73%. Biomea Fusion has a consensus price target of $8.20, indicating a potential upside of 378.13%. Given Biomea Fusion's higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Foghorn Therapeutics has a beta of 2.89, suggesting that its share price is 189% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market.

In the previous week, Biomea Fusion had 3 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 1 mentions for Foghorn Therapeutics. Biomea Fusion's average media sentiment score of 0.72 beat Foghorn Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biomea Fusion	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biomea Fusion has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -175.78%. Foghorn Therapeutics' return on equity of 0.00% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-175.78%	N/A	-31.17%
Biomea Fusion	N/A	-253.73%	-97.91%

Biomea Fusion has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	13.41	-$74.28M	-$0.98	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

Summary

Biomea Fusion beats Foghorn Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Biomea Fusion compare to DiaMedica Therapeutics?

Biomea Fusion (NASDAQ:BMEA) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

DiaMedica Therapeutics' return on equity of -77.76% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-253.73%	-97.91%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Biomea Fusion has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biomea Fusion presently has a consensus target price of $8.20, suggesting a potential upside of 378.13%. DiaMedica Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 79.02%. Given Biomea Fusion's stronger consensus rating and higher possible upside, equities analysts plainly believe Biomea Fusion is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Biomea Fusion had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 0 mentions for DiaMedica Therapeutics. Biomea Fusion's average media sentiment score of 0.72 beat DiaMedica Therapeutics' score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.

Company	Overall Sentiment
Biomea Fusion	Positive
DiaMedica Therapeutics	Neutral

Summary

Biomea Fusion beats DiaMedica Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Century Therapeutics?

Century Therapeutics (NASDAQ:IPSC) and Biomea Fusion (NASDAQ:BMEA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, Biomea Fusion had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 4 mentions for Biomea Fusion and 2 mentions for Century Therapeutics. Century Therapeutics' average media sentiment score of 1.57 beat Biomea Fusion's score of 0.72 indicating that Century Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Century Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biomea Fusion	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 2.4% of Century Therapeutics shares are owned by insiders. Comparatively, 10.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Century Therapeutics' return on equity of -49.51% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Century Therapeutics	N/A	-49.51%	-38.09%
Biomea Fusion	N/A	-253.73%	-97.91%

Century Therapeutics has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market.

Century Therapeutics presently has a consensus price target of $4.75, indicating a potential upside of 117.49%. Biomea Fusion has a consensus price target of $8.20, indicating a potential upside of 378.13%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Biomea Fusion is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Century Therapeutics	N/A	N/A	-$9.58M	-$0.93	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A

Summary

Biomea Fusion beats Century Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Biomea Fusion compare to Sagimet Biosciences?

Biomea Fusion (NASDAQ:BMEA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 10.6% of Biomea Fusion shares are held by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Biomea Fusion has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.37, suggesting that its share price is 237% more volatile than the broader market.

Sagimet Biosciences' return on equity of -31.96% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-253.73%	-97.91%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Sagimet Biosciences has higher revenue and earnings than Biomea Fusion. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.29	N/A
Sagimet Biosciences	$2M	318.73	-$51.04M	-$1.28	N/A

Biomea Fusion currently has a consensus price target of $8.20, suggesting a potential upside of 378.13%. Sagimet Biosciences has a consensus price target of $29.17, suggesting a potential upside of 184.41%. Given Biomea Fusion's stronger consensus rating and higher probable upside, equities research analysts plainly believe Biomea Fusion is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Biomea Fusion and Biomea Fusion both had 4 articles in the media. Sagimet Biosciences' average media sentiment score of 0.97 beat Biomea Fusion's score of 0.72 indicating that Sagimet Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sagimet Biosciences beats Biomea Fusion on 8 of the 13 factors compared between the two stocks.

Get Biomea Fusion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BMEA vs. The Competition

Export

Metric	Biomea Fusion	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$124.38M	$4.04B	$7.33B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-5.92	11.73	271.22	24.16
Price / Sales	N/A	1,431.77	696.48	128.34
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	4.08	17.51	11.33	6.51
Net Income	-$61.80M	-$22.72M	$3.46B	$347.63M
7 Day Performance	27.04%	4.59%	2.92%	1.50%
1 Month Performance	37.20%	12.04%	8.55%	5.15%
1 Year Performance	-5.25%	60.45%	27.54%	17.73%

Biomea Fusion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BMEA Biomea Fusion	2.2579 of 5 stars	$1.72 +7.9%	$8.20 +378.1%	-13.1%	$124.38M	N/A	N/A	50	News Coverage Analyst Forecast Options Volume Gap Up High Trading Volume
RCKT Rocket Pharmaceuticals	2.5698 of 5 stars	$3.40 -2.0%	$8.57 +152.1%	-3.0%	$380.92M	N/A	N/A	240
FHTX Foghorn Therapeutics	1.9474 of 5 stars	$6.74 +7.7%	$11.43 +69.6%	+23.6%	$371.75M	$30.91M	N/A	120
DMAC DiaMedica Therapeutics	1.5663 of 5 stars	$6.62 -0.9%	$12.00 +81.3%	+6.7%	$360.23M	N/A	N/A	20
IPSC Century Therapeutics	2.0916 of 5 stars	$1.95 +1.6%	$4.75 +143.6%	+291.7%	$346.28M	$109.16M	N/A	170	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BMEA) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biomea Fusion (BMEA) Competitors

BMEA vs. RCKT, FHTX, DMAC, IPSC, and SGMT

How does Biomea Fusion compare to Rocket Pharmaceuticals?

Summary

How does Biomea Fusion compare to Foghorn Therapeutics?

Summary

How does Biomea Fusion compare to DiaMedica Therapeutics?

Summary

How does Biomea Fusion compare to Century Therapeutics?

Summary

How does Biomea Fusion compare to Sagimet Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biomea Fusion (BMEA) Competitors

BMEA vs. RCKT, FHTX, DMAC, IPSC, and SGMT

How does Biomea Fusion compare to Rocket Pharmaceuticals?

Is BMEA or RCKT more profitable?

Which has preferable earnings & valuation, BMEA or RCKT?

Do insiders and institutionals hold more shares of BMEA or RCKT?

Does the media favor BMEA or RCKT?

Do analysts prefer BMEA or RCKT?

Which has more volatility & risk, BMEA or RCKT?

Summary

How does Biomea Fusion compare to Foghorn Therapeutics?

Do analysts rate FHTX or BMEA?

Which has more volatility and risk, FHTX or BMEA?

Does the media refer more to FHTX or BMEA?

Do insiders & institutionals have more ownership in FHTX or BMEA?

Is FHTX or BMEA more profitable?

Which has preferable earnings & valuation, FHTX or BMEA?

Summary

How does Biomea Fusion compare to DiaMedica Therapeutics?

Is BMEA or DMAC more profitable?

Which has preferable valuation and earnings, BMEA or DMAC?

Which has more volatility and risk, BMEA or DMAC?

Do institutionals and insiders hold more shares of BMEA or DMAC?

Do analysts recommend BMEA or DMAC?

Does the media refer more to BMEA or DMAC?

Summary

How does Biomea Fusion compare to Century Therapeutics?

Does the media prefer IPSC or BMEA?

Do institutionals & insiders believe in IPSC or BMEA?

Is IPSC or BMEA more profitable?

Which has more risk & volatility, IPSC or BMEA?

Do analysts prefer IPSC or BMEA?

Which has stronger valuation & earnings, IPSC or BMEA?

Summary

How does Biomea Fusion compare to Sagimet Biosciences?

Do institutionals & insiders hold more shares of BMEA or SGMT?

Which has more risk & volatility, BMEA or SGMT?

Is BMEA or SGMT more profitable?

Which has preferable valuation & earnings, BMEA or SGMT?

Do analysts prefer BMEA or SGMT?

Does the media favor BMEA or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BMEA vs. The Competition

Biomea Fusion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools